Table 2.
Univariate association between clinical predictors of low disease activity (defined by baseline DAS28-CRP ⩽3.2) in participants on MTX monotherapy
| Baseline variables | DAS28-CRP ⩽3.2 (n = 35) | DAS28-CRP >3.2 (n = 85) | OR (95% CI) | P-value |
|---|---|---|---|---|
| Age, mean (s.d.), yrs | 55.3 (14.4) | 63.9 (10.9) | – | 0.003 |
| Gender (female), n (%) | 29 (82.9) | 74 (87.1) | 0.72 (0.24, 2.12) | 0.57 |
| Current smokers, n (%) | 3 (9.7) | 5 (6.3) | 1.61 (0.36, 7.17) | 0.68 |
| RF positive, n (%) | 26 (74.3) | 69 (79.8) | 0.67 (0.26, 1.70) | 0.46 |
| Anti-CCP positive, n (%) | 19 (55.9) | 67 (79.8) | 0.32 (0.14, 0.76) | 0.01 |
| Disease duration, mean (s.d.), yrs | 12.9 (12.5) | 20.2 (12.7) | 0.26 (0.11, 0.62) | 0.002 |
| MDHAQ score, mean (s.d.) | 0.6 (0.5) | 0.7 (0.6) | – | 0.23 |
| Duration of MTX treatment, mean (s.d.), months | 58.8 (63.2) | 80.5 (81.7) | – | 0.65 |
| MTX dose, mean (s.d.), mg | 12.0 (7.5) | 13.5 (7.0) | – | 0.28 |
| Past DMARD users, n (%) | 24 (68.6) | 67 (78.2) | 0.59 (0.24, 1.42) | 0.25 |
| Past anti-TNF users, n (%) | 4 (11.4) | 8 (9.4) | 1.24 (0.35, 4.42) | 0.74 |